Share us 

  • Facebook - Grey Circle
  • Twitter - Grey Circle
  • Google+ - Grey Circle
  • Instagram - Grey Circle

© 2018 TSI Inc. 


September 5, 2018

Phase II Trial of HisproUK, Low-Dose tPA Dual Therapy for Ischemic Stroke Initiated - NeurologyLive 

Thrombolytic Science Initiates Phase 2 Clinical Trial of its Novel Treatment Regimen for Ischemic Stroke; Press Release 


May 30, 2018

Thrombolytic Science to Participate in 2018 BIO International Conference; Press Release


May 24, 2018

TSI presents at the 15th Anglo Nordic Life Science Investor Conference being held in London; Press Release


December 14, 2017

TSI welcomes Annalisa Jenkins, MBBS, FRCP, as a non-executive board member; Press Release


November 15, 2017

TSI appoints Michael Woehler, PhD, Chairman of the board; Press Release

September 18, 2017

TSI's first-in-man, randomized, double-blind, placebo-controlled Phase 1 clinical trial demonstrates safety and tolerability of TS01, a sequence of low doses of tPA and HisproUK; Press Release


November 18, 2015

TSI, LLC nominated as a Top Biopharma Project to Watch in Cardiovascular by Elsevier Business Intelligence’s Therapeutic Area Partnership Conference organizers. Read more: TSI LLC nominated as a Top Biopharma Project to Watch

  • White LinkedIn Icon
  • White Twitter Icon